IDF creating new Type 2 diabetes guidelines with global experts, focusing on patient-centered care and global accessibility.

Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

“It’s clear from today’s discussion that an FDA-approved treatment and clear education on managing risk is urgently needed, and we believe our data supports this need,” said Dr Mike Exton, chief ...

These two competitors have made a habit of conducting clinical trials against each other, seeking to one-up the other’s latest diabetes treatment. This is obviously a welcome sight for the 35 ...